WHO Prequalification (PQ)

WHO PQ Rejections and Deficiencies? Practical Submission and Compliance Solutions

Identifying the warning signs of potential WHO PQ submission failures is critical for swift remediation. Symptoms may manifest from various sources, including manufacturing processes, quality control tests, and documentation reviews.…

API change not reported during dossier submission – preventing PQ suspension

Recognizing the early indicators of unreported API changes is crucial. Symptoms may vary depending on the stage of the manufacturing process, but here are common signs to monitor:Click to read…

API change not reported during requalification – documentation gaps reviewers flag

Identifying early warning signals is crucial in the effective management of API change documentation. Symptoms indicating potential issues may include:Click to read the full article.

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

Recognizing the symptoms of PQ dossier deficiencies early is crucial for timely corrective measures. Common signals include:Click to read the full article.

Manufacturing site not PQ-ready during WHO PQ assessment – CAPA expectations for PQ approval

Identifying early warning signs is crucial for timely intervention when a manufacturing site is deemed not PQ-ready. Symptoms may manifest in various forms within the production environment and laboratory settings.…

Deviation history questioned during requalification – preventing PQ suspension

Recognizing signs of deviation or non-compliance is crucial. Common symptoms include:Click to read the full article.

Stability data gaps during variation management – preventing PQ suspension

Recognizing the early signs of stability data gaps is key to preventing larger issues. Common symptoms include:Click to read the full article.

Deviation history questioned during variation management – preventing PQ suspension

Identifying symptoms of potential deviations is crucial to managing quality effectively. Symptoms can manifest in several ways:Click to read the full article.

CAPA effectiveness doubted during dossier submission – preventing PQ suspension

Identifying early symptoms or signals of potential CAPA effectiveness issues is essential. Here are prevalent signs that indicate CAPA deficiencies:Click to read the full article.

PQ dossier deficiency during WHO PQ assessment – preventing PQ suspension

Actionable Playbook for Addressing PQ Dossier Deficiency in WHO Assessments Ensuring compliance during a WHO PQ assessment is crucial for pharmaceutical companies aiming for international recognition. However, deficiencies in the…

PQ dossier deficiency during dossier submission – preventing PQ suspension

Identifying the early warning signs of PQ dossier deficiencies is critical in preventing more severe repercussions. Common symptoms include:Click to read the full article.

API change not reported during requalification – how to defend manufacturing readiness

Recognizing symptoms of unreported API changes is crucial for prompt intervention. Common indicators include:Click to read the full article.